About Us

Decheng Capital is a leading investment firm that provides capital and strategic support to early stage life science companies with revolutionary technologies and growth stage healthcare companies with strong market presence. We are a group of dedicated professionals with complementary expertise who have outstanding track records of building highly successful companies globally. Founded in 2012, Decheng continues to capitalize on a historic opportunity in the rapid growth of healthcare industry as well as breakthroughs in life science research. With over $2 billion in capital under management and support from some of the most prestigious LPs in the world, Decheng is poised to deliver superior returns for our investors and create value for our entrepreneur partners.


Founded in 2012

Asset Under Management

Over $2 billion of capital

Your Partner

Preferred partners for entrepeneurs, world-class scientists and strategic partners

Recent News

November 16, 2021

ACELYRIN, INC. Closes $250 Million Series B Financing and Announces Licensing of Izokibep

October 26, 2021

Vertex signs another Mammoth-sized CRISPR deal with $650M in Biobucks on the Line

September 24, 2021

Google Provider of At-home Covid-19 tests is Now a $3 Billion Company Traded on Nasdaq


November 10, 2020

Exclusive: Decheng's Inside View of Merck's $2.75 Billion Acquisition of VelosBio                                               

October 12, 2020

Exclusive: How Sequencing Firm ReadCoor Came to be Acquired by 10x Genomics                                   

September 23, 2020

Exclusive: The Story Behind How Cirina, a $12 Million Hong Kong Diagnostics Startup, Became Part of Illumina